Overview

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Sevelamer
Criteria
Inclusion Criteria:

- Serum phosphate level greater than (>) 5.5 milligram per deciliter (mg/dL) (1.78
millimole per liter [mmol/L]) after discontinuation of current phosphate binder
therapy

- Men or women 18 years or older

Exclusion Criteria:

- Have active dysphagia or swallowing disorder or a predisposition to or current bowel
obstruction, ileus, or severe gastrointestinal motility disorders including severe
constipation